– USA, MA – Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the appointment of Laurie Olson to its Board of Directors, effective April 27, 2021.
“We are pleased to welcome Laurie to our board as we continue to scale the business and capitalize on the tremendous market opportunity ahead,” said Chairman and CEO, Kevin Hrusovsky. “Laurie’s philosophy that the needs of patients are best realized via deep customer insights and data-driven decisions integrates seamlessly with Quanterix’ broader precision health mission. We believe her business acumen and far-reaching expertise in commercial and corporate strategy will be a valuable addition to our very skilled and knowledgeable board.”
About Laurie Olson
Laurie Olson is a seasoned pharmaceutical executive who brings more than three decades of experience in commercial and corporate strategy from Pfizer, Inc. to the Quanterix Board. She most recently served as executive vice president, strategy and commercial operations at Pfizer until 2018, where she led a team of approximately 2,000 people across 100 markets, with a scope including corporate strategy, market access and reimbursement, digital strategy, portfolio management, business analytics, and global commercial operations. She also served as a member of Pfizer’s executive leadership team.
Olson also serves on the Board of Directors of Karuna Therapeutics, a clinical-stage biopharmaceutical company committed to developing novel therapies for neuropsychiatric disorders.
During her career at Pfizer, Olson also served as a member of the Pfizer Board of Directors Science and Technology Committee, where she informed therapeutic area strategies and the utilization of new technologies and analytics to drive R&D productivity. As a member of the Company’s Business Development, Portfolio, Disclosure, Diversity, and Compliance Committees, Olson developed M&A strategies, ensured rigorous capital allocation, and maintained Pfizer’s transparency and compliance commitments with stakeholders.
“I am honored to be appointed to Quanterix’ Board of Directors at such a pivotal moment for biomarker research when technologies like Simoa are increasingly being called upon to detect, measure and inform disease treatment,” said Laurie Olson. “I look forward to working alongside Kevin and the board, utilizing the expertise I’ve gained across several roles within the pharmaceutical industry, to advance Quanterix’ mission of transforming the way healthcare is provided.”
Olson is also a member of the Board of Trustees at the Mystic Seaport Museum in Mystic, CT. She received her BA in economics from the State University of New York at Stony Brook and earned her MBA in marketing from Hofstra University.
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, has the potential to change how healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses, and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation, and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
For more information: https://www.quanterix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.